Supreme Court Urged To Deny Saw Palmetto Health Claim Review
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court should refuse to consider the appropriateness of a proposed saw palmetto/prostatic hyperplasia health claim due to the petitioners' misinterpretation of the FD&C Act, Acting Solicitor General Paul Clemente maintains
You may also be interested in...
Saw Palmetto Claims Appeal Shot Down; Emord Eyes Supreme Court
The Washington, D.C. federal appeals court upheld FDA's denial of a health claim petition linking saw palmetto extract to treatment of benign prostatic hypertrophy
FDA Prohibition of Saw Palmetto/BPH Treatment Claim Upheld by Court
FDA's decision to deny a health claim linking saw palmetto extract to the treatment of benign prostatic hypertrophy symptoms was upheld by a Washington, D.C. federal court in a Jan. 3 decision
FDA Denial Of Saw Palmetto Health Claim For BPH Prompts Lawsuit
FDA's denial of a health claim relating to saw palmetto and benign prostatic hyperplasia violates the First Amendment, the Nutrition Labeling & Education Act (NLEA) and the Administrative Procedures Act (APA), Washington, D.C.-based Emord & Associates asserts in a suit filed Dec. 7.